Skip Nav Destination
Close Modal
1-20 of 499
Search Results for pharmaceutical industry
Follow your search
Access your saved searches in your account
Would you like to receive an alert when new items match your search?
1
Journal Article
Self-Regulation in the Pharmaceutical Industry: The Exposure of Children and Adolescents to Erectile Dysfunction Commercials
Available to Purchase
J Health Polit Policy Law (2019) 44 (5): 765–787.
Published: 01 October 2019
... regulation of DTCA. These organizations argue that the negative impact of such advertising outweighs the informational value claimed by the pharmaceutical industry. The industry maintains that further restrictions on DTCA are not warranted because it is successfully self-regulating via “guiding principles...
FIGURES
| View All (4)
View articletitled, Self-Regulation in the <span class="search-highlight">Pharmaceutical</span> <span class="search-highlight">Industry</span>: The Exposure of Children and Adolescents to Erectile Dysfunction Commercials
View
PDF
for article titled, Self-Regulation in the <span class="search-highlight">Pharmaceutical</span> <span class="search-highlight">Industry</span>: The Exposure of Children and Adolescents to Erectile Dysfunction Commercials
Journal Article
Partial Progress: Governing the Pharmaceutical Industry and the Nhs, 1948–2008
Available to Purchase
J Health Polit Policy Law (2009) 34 (6): 931–977.
Published: 01 December 2009
...John Abraham Coinciding with sixty years of the U.K. National Health Service (NHS), this article reviews the neglected area of the governance of the pharmaceutical industry and the NHS. It traces the relationships between the pharmaceutical industry, the state, and the NHS from the creation...
View articletitled, Partial Progress: Governing the <span class="search-highlight">Pharmaceutical</span> <span class="search-highlight">Industry</span> and the Nhs, 1948–2008
View
PDF
for article titled, Partial Progress: Governing the <span class="search-highlight">Pharmaceutical</span> <span class="search-highlight">Industry</span> and the Nhs, 1948–2008
Journal Article
Challenging Pharmaceutical Industry Political Power in Maine and Vermont
Available to Purchase
J Health Polit Policy Law (2003) 28 (1): 109–132.
Published: 01 February 2003
...Ramón Castellblanch A comparison of the Vermont and Maine cases of attempting to control pharmaceutical prices in the year 2000 shows that the Maine legislators were more successful in challenging pharmaceutical industry political power. This comparison shows that challenging the industry...
View articletitled, Challenging <span class="search-highlight">Pharmaceutical</span> <span class="search-highlight">Industry</span> Political Power in Maine and Vermont
View
PDF
for article titled, Challenging <span class="search-highlight">Pharmaceutical</span> <span class="search-highlight">Industry</span> Political Power in Maine and Vermont
Journal Article
The Politics and Strategy of Industry Self-Regulation: The Pharmaceutical Industry's Principles for Ethical Direct-to-Consumer Advertising as a Deceptive Blocking Strategy
Available to Purchase
J Health Polit Policy Law (2013) 38 (3): 505–544.
Published: 01 June 2013
...Denis G. Arnold; James L. Oakley As the pharmaceutical industry lobbies European regulators to permit direct-to-consumer advertising (DTCA) of prescription drugs in the European Union, we found that five leading companies violated industry-developed and -promulgated standards for ethical...
View articletitled, The Politics and Strategy of <span class="search-highlight">Industry</span> Self-Regulation: The <span class="search-highlight">Pharmaceutical</span> <span class="search-highlight">Industry's</span> Principles for Ethical Direct-to-Consumer Advertising as a Deceptive Blocking Strategy
View
PDF
for article titled, The Politics and Strategy of <span class="search-highlight">Industry</span> Self-Regulation: The <span class="search-highlight">Pharmaceutical</span> <span class="search-highlight">Industry's</span> Principles for Ethical Direct-to-Consumer Advertising as a Deceptive Blocking Strategy
Journal Article
Challenges with Defining Pharmaceutical Markets and Potential Remedies to Screen for Industry Consolidation
Available to Purchase
J Health Polit Policy Law (2022) 47 (5): 583–607.
Published: 01 October 2022
...Robin Feldman; Brent D. Fulton; Jamie R. Godwin; Richard M. Scheffler Abstract Context: Dramatic increases in pharmaceutical merger and acquisition (M&A) activity since 2010 suggest we are in the midst of a third wave of industry consolidation. Methods: The authors reviewed 168 economic, legal...
View articletitled, Challenges with Defining <span class="search-highlight">Pharmaceutical</span> Markets and Potential Remedies to Screen for <span class="search-highlight">Industry</span> Consolidation
View
PDF
for article titled, Challenges with Defining <span class="search-highlight">Pharmaceutical</span> Markets and Potential Remedies to Screen for <span class="search-highlight">Industry</span> Consolidation
Journal Article
Policy Making on Data Exclusivity in the European Union: From Industrial Interests to Legal Realities
Available to Purchase
J Health Polit Policy Law (2009) 34 (6): 979–1010.
Published: 01 December 2009
...Sandra Adamini; Hans Maarse; Esther Versluis; Donald W. Light After lengthening the duration of patents to twenty years in 1984, the pharmaceutical industry has turned to data exclusivity as a major vehicle for extending market protection, even after patents expire. Such protections give companies...
View articletitled, Policy Making on Data Exclusivity in the European Union: From <span class="search-highlight">Industrial</span> Interests to Legal Realities
View
PDF
for article titled, Policy Making on Data Exclusivity in the European Union: From <span class="search-highlight">Industrial</span> Interests to Legal Realities
Journal Article
Industry Payments to Physicians Are Kickbacks. How Should Stakeholders Respond?
Available to Purchase
J Health Polit Policy Law (2022) 47 (6): 815–833.
Published: 01 December 2022
...Aaron Mitchell; Ameet Sarpatwari; Peter B. Bach Abstract Payments from the pharmaceutical industry to US physicians are common. In determining which payments rise to the level of an illegal kickback under the Anti-Kickback Statute (AKS), the Department of Health and Human Services' Office...
Journal Article
Marketing Opioids to Veterans and Older Adults: A Content Analysis of Internal Industry Documents Released from State of Oklahoma v. Purdue Pharma LP, et al.
Available to Purchase
J Health Polit Policy Law (2022) 47 (4): 453–472.
Published: 01 August 2022
..., while opioid prescriptions for older adults increased ninefold between 1995 and 2010. Methods: We reviewed internal pharmaceutical industry documents released in legal discovery to determine how companies targeted these groups to increase prescribing and sales. This review included an analysis...
View articletitled, Marketing Opioids to Veterans and Older Adults: A Content Analysis of Internal <span class="search-highlight">Industry</span> Documents Released from State of Oklahoma v. Purdue Pharma LP, et al.
View
PDF
for article titled, Marketing Opioids to Veterans and Older Adults: A Content Analysis of Internal <span class="search-highlight">Industry</span> Documents Released from State of Oklahoma v. Purdue Pharma LP, et al.
Includes: Supplementary data
Journal Article
Does Increased Spending on Pharmaceutical Marketing Inhibit Pioneering Innovation?
Available to Purchase
J Health Polit Policy Law (2016) 41 (2): 157–179.
Published: 01 April 2016
...Denis G. Arnold; Jennifer L. Troyer Abstract The pharmaceutical industry has been criticized for developing and aggressively marketing drugs that do not provide significant health benefits relative to existing drugs but retain the benefits of patent protection. Critics argue that drug marketing...
FIGURES
Journal Article
Maximum Allowable Cost: Can the Government Control Drug Costs? A Retrospective Political Analysis of Events and Issues
Available to Purchase
J Health Polit Policy Law (1979) 4 (2): 155–175.
Published: 01 April 1979
... to control prices of pharmaceuticals, prior to enactment of some form of national health insurance, if successful, will call forth pharmaceutical industry strategies which could negate program benefits. Copyright © 1979 by the Dept. of Health Administration, Duke University 1979 The authors wish...
Journal Article
The Political Economy of Market Power in Pharmaceuticals
Available to Purchase
J Health Polit Policy Law (2023) 48 (2): 215–239.
Published: 01 April 2023
...Amy Kapczynski Abstract The pharmaceutical industry is among the most politically powerful business sectors in the United States today. This article describes how this industry has successfully entrenched its power, with attention to four sources of power: property power, vertical power over...
Journal Article
No Exit and the Organization of Voice in Biotechnology and Pharmaceuticals
Available to Purchase
J Health Polit Policy Law (2003) 28 (2-3): 473–508.
Published: 01 June 2003
...” is usually applied to the individual or consumer level,this article develops the concept of organized voice and illustrates how it has exhibited leadership in the controversial relations between the biotech and pharmaceutical industries and society as a whole. The essay concludes by urging more research...
Journal Article
The Rhetorical Transformations and Policy Failures of Prescription Drug Pricing Reform under the Trump Administration
Available to Purchase
J Health Polit Policy Law (2021) 46 (6): 1053–1068.
Published: 01 December 2021
...Rachel E. Sachs Abstract Throughout his four years in office, President Trump made prescription drug pricing a focus of his policy agenda. President Trump not only used strong language to criticize the pharmaceutical industry and its practices but also introduced ambitious reform policies that had...
Journal Article
International Reference Pricing in the Context of US Drug Policy
Available to Purchase
J Health Polit Policy Law (2022) 47 (6): 779–796.
Published: 01 December 2022
...Richard Frank; Rena M. Conti; Jonathan Gruber Abstract International reference prices (IRP), also called external reference prices, are widely used across developed nations. IRP uses the prices paid in other countries to either inform negotiations with the pharmaceutical industry or as a cap...
Journal Article
Pharmaceutical Regulation in the European Community: Barriers to Single Market Integration
Available to Purchase
J Health Polit Policy Law (1992) 17 (4): 847–868.
Published: 01 August 1992
...Louis H. Orzack; Kenneth I. Kaitin; Louis Lasagna The European Community (EC) plans to create a single market for pharmaceutical medicines, but the drug industry is closely linked to cultural and societal values concerning health; to the national regulatory agencies responsible for the evaluation...
View articletitled, <span class="search-highlight">Pharmaceutical</span> Regulation in the European Community: Barriers to Single Market Integration
View
PDF
for article titled, <span class="search-highlight">Pharmaceutical</span> Regulation in the European Community: Barriers to Single Market Integration
Journal Article
Emergent Patterns in the Regulation of Pharmaceuticals: Institutions and Interests in the United States, Canada, Britain, and France
Available to Purchase
J Health Polit Policy Law (2003) 28 (4): 615–658.
Published: 01 August 2003
...Mary E. Wiktorowicz Although industrialized nations regulate pharmaceuticals to ensure their safety and efficacy, they balance these concerns with those related to the timeliness of the approval process and the burdens involved in meeting regulatory criteria. The United States, Canada, Britain...
View articletitled, Emergent Patterns in the Regulation of <span class="search-highlight">Pharmaceuticals</span>: Institutions and Interests in the United States, Canada, Britain, and France
View
PDF
for article titled, Emergent Patterns in the Regulation of <span class="search-highlight">Pharmaceuticals</span>: Institutions and Interests in the United States, Canada, Britain, and France
Journal Article
Inside “Operation Change Agent”: Mallinckrodt's Plan for Capturing the Opioid Market
Available to Purchase
J Health Polit Policy Law (2024) 49 (4): 599–630.
Published: 01 August 2024
.... https://www.industrydocuments.ucsf.edu/docs/thvf0236 . References Abraham John . 2002 . “ The Pharmaceutical Industry as a Political Player .” Lancet 360 , no. 9344 : 1498 – 1502 . https://doi.org/10.1016/S0140-6736(02)11477-2 . Abraham John . 2009 . “ The Pharmaceutical...
FIGURES
Journal Article
Misleading Congress About Drug Development: Reply
Available to Purchase
J Health Polit Policy Law (2008) 33 (2): 319–324.
Published: 01 April 2008
... -111. Waltham, MA: PAREXEL International. Public Citizen. 2001 . Rx R&D Myths: The Case Against the Drug Industry's R&D Scare Card . July 23. www.citizen.org/documents/rdmyths.pdf . Scherer, F. M., 1993 . Pricing, Profits, and Technological Progress in the Pharmaceutical Industry...
Journal Article
Bad Medicine: The Prescription Drug Industry in the Third World
Available to Purchase
J Health Polit Policy Law (1994) 19 (4): 922–924.
Published: 01 August 1994
..., and Philip R. Lee. Bad Medicine:
The Rvscription DNg Industry in the Third World. Stanford, CA:
Stanford University Press, 1992. 358 pp. $29.95 cloth.
The multinational pharmaceutical industry is no stranger to vilification
from government officials, health policy analysts, consumer advocates...
Journal Article
Contested Ground: Public Purpose and Private Interest in the Regulation of Prescription Drugs
Available to Purchase
J Health Polit Policy Law (1998) 23 (2): 395–396.
Published: 01 April 1998
... swirling around concerning the
pharmaceutical industry. There is little that is new in these articles, but
much that is useful.
Davis has divided the articles into three rather different sections. The
first section is mostly sociology. The articles discuss the growth of what
can be called a medical...
1
